Dayvigo (Lemborexant) FAERS Safety Signals: Post-Market Surveillance Data

The direct answer

Dayvigo's post-market adverse event reports in FAERS reproduce the safety profile already disclosed in its FDA label and shared across the DORA class (lemborexant and suvorexant): next-day somnolence, sleep paralysis, complex sleep behaviors such as sleepwalking or sleep-driving, and psychiatric events including suicidal ideation. Nothing in publicly summarized FAERS activity for this drug has triggered a boxed warning, a Risk Evaluation and Mitigation Strategy, or an FDA safety communication specific to lemborexant beyond the class-wide warning that predates its approval. The practical question for a prescriber or patient is not whether these events appear in FAERS, since spontaneous-report databases will always accumulate case reports for a widely prescribed sedative-hypnotic, but whether a specific patient's risk factors (psychiatric comorbidity, prior parasomnia, interacting medications, need to drive or wake early) change the calculus enough to avoid the drug, start lower, or monitor more closely.

Disambiguation and what this page covers

Lemborexant is sold under the brand name Dayvigo. It is a small-molecule dual orexin receptor antagonist, distinct from benzodiazepine receptor agonists (zolpidem, eszopiclone) and from melatonin receptor agonists (ramelteon). Its only FDA-approved indication is insomnia in adults, based on the SUNRISE trial program. This page discusses FAERS-reported adverse events and label-based safety information; it does not cover dosing for an individual patient, and it is not a substitute for the current FDA-approved prescribing information, which should be checked directly for the latest label language.

What FAERS is and what it cannot tell you

FAERS is a database of voluntary adverse event reports submitted by patients, clinicians, and manufacturers after a drug reaches the market (FDA, FAERS overview). It is designed for signal detection, not for calculating how often an event actually occurs. Reporting is voluntary, so it is affected by underreporting of common or expected events and by "stimulated reporting," in which media coverage or litigation around a specific adverse event (such as sleep-driving) increases the volume of reports about that event independent of any underlying change in risk. A frequently observed pattern with newly approved drugs, called the Weber effect, is a reporting surge in the first one to two years after launch that tapers even without a change in the drug's actual safety. The database also lacks a reliable denominator: the true number of patients exposed to lemborexant is estimated from prescription data rather than counted directly, which means raw report counts or ratios built from them cannot be converted into a rate or an individual patient's risk.

This is the load-bearing paragraph for this page: FAERS signals for lemborexant, including sleep paralysis and complex sleep behavior reports, are useful for confirming that a known class-level risk continues to appear in real-world use, but they cannot establish how common that risk is for an individual patient, and they cannot by themselves distinguish a true drug effect from reporting artifact. Any specific reporting-odds-ratio figure attached to lemborexant should be treated as unverified until checked against a peer-reviewed pharmacovigilance analysis, because such figures are easy to misstate or misattribute.

What the pivotal trial data show, and where the trial's limits matter

Lemborexant's approval rested on the SUNRISE trial program, which studied adults with insomnia, including a large trial enrolling adults aged 55 and older, comparing lemborexant 5 mg and 10 mg against placebo (and, in one trial, an active comparator) over about a month of treatment. In that program, somnolence was the most commonly reported adverse event and occurred more often at 10 mg than at 5 mg or placebo; sleep paralysis was also reported more often on lemborexant than on placebo. Exact percentages for these events are published in the trial's primary report, but this draft does not attach a specific number to them because the identifying source could not be independently confirmed during this review pass; an editor with direct access to the published trial or the FDA label should insert verified figures before publication.

The trial duration, roughly a month in the pivotal studies, is short relative to how long patients actually take a nightly sleep aid. Adverse events with delayed onset or that accumulate with chronic exposure, such as complex sleep behaviors that emerge after dose changes, cumulative next-day cognitive effects, or psychiatric symptom changes over months, are not well captured by a 30-night trial. Post-market surveillance exists specifically to fill that gap, which is also why FAERS reports for this drug deserve attention even though they cannot be converted into incidence rates.

Somnolence and next-day impairment

Next-day somnolence is a labeled and expected effect of lemborexant, consistent with its mechanism (orexin receptor blockade) and its long elimination half-life relative to a typical night's sleep. The FDA label instructs patients not to drive or operate machinery until they know how the drug affects them the next morning, and it recommends 5 mg as the starting dose, with 10 mg reserved for patients who do not respond adequately. Patients who cannot commit to a full night (commonly described as at least 7 hours) of sleep opportunity after dosing are at higher risk of residual impairment the next day. FAERS reports attributed to this category include motor vehicle incidents and falls tied to residual sedation, which is the expected downstream consequence of a labeled effect rather than a new or unexpected signal.

Sleep paralysis and other REM-intrusion events

Orexin neurons help stabilize the boundary between wakefulness and REM sleep. Blocking this signaling, which is the intended mechanism of any DORA, can produce REM-intrusion phenomena: sleep paralysis (waking with intact awareness but transient muscle atonia), and hypnagogic or hypnopompic hallucinations. This mechanism is described in the pharmacology literature on orexin signaling and is consistent with the clinical parallel to narcolepsy, a disease of orexin neuron loss. Sleep paralysis is listed as a known adverse reaction in the lemborexant label. Patients experiencing recurrent sleep paralysis are generally managed with dose reduction to 5 mg; if paralysis continues at the lower dose, moving to an alternative insomnia treatment is reasonable to discuss with a prescriber. Specific rates of sleep paralysis reported in the pivotal trial and specific FAERS disproportionality figures are omitted here because they require verification against a primary source rather than being restated from an unconfirmed prior draft.

Complex sleep behaviors

Before lemborexant's approval, the FDA required all orexin receptor antagonists and most other sedative-hypnotics to carry warning language about complex sleep behaviors, including sleepwalking, sleep-driving, and other activities performed with no memory of them afterward (an FDA safety communication issued in 2019). That communication predates lemborexant's approval and applies to the class rather than singling out this drug. FAERS reports for lemborexant that describe sleep-eating, sleep-cooking, or leaving the home while asleep fall within this already-recognized class risk. FDA guidance is unambiguous that a single episode of complex sleep behavior is grounds to stop the medication; dose reduction is not an appropriate first response to a sleepwalking or sleep-driving event.

Suicidal ideation reports: a signal that is hard to interpret in isolation

FAERS reports for lemborexant include suicidal ideation and worsening depression. This signal is genuinely difficult to interpret for two reasons. First, insomnia itself is an independent risk marker for suicidal ideation, so a population prescribed a hypnotic is not a population at baseline psychiatric risk. Second, the SUNRISE trials excluded patients with active major depressive disorder or significant psychiatric illness, so the pre-approval safety database underrepresents the psychiatric comorbidity common among people actually prescribed sleep medication in practice. FAERS, drawing from real-world prescribing, will naturally surface more psychiatric adverse events than a trial population selected to exclude them. The lemborexant label carries a warning that worsening depression and suicidal ideation have been reported with sedative-hypnotics generally, and it advises screening for psychiatric comorbidity before starting the drug. Whether DORAs carry a mood effect beyond that of sedative-hypnotics as a class is an open question; animal data on orexin's role in reward and motivation exist, but translation to a clinical human signal has not been established and should not be overstated.

Label evolution and drug interactions worth flagging

The FDA label for lemborexant contraindicates coadministration with strong CYP3A inhibitors (for example, ketoconazole, itraconazole, clarithromycin) because these drugs substantially raise lemborexant exposure, and it requires dose reduction with moderate CYP3A inhibitors (for example, fluconazole, diltiazem, verapamil). This interaction matters clinically because the margin between an effective dose and an oversedating one is narrow. Anyone reconciling dosing around a specific interacting medication should check the current FDA label directly, since prescribing information is revised over time and specific magnitude figures (such as fold-change in exposure) are not restated here without a verified current source.

Lemborexant versus suvorexant: what is and is not comparable

Suvorexant (Belsomra), the first DORA approved in the United States (2014), has a longer post-market history than lemborexant. Both drugs share the same class-level warnings: complex sleep behaviors, next-day impairment, and psychiatric adverse event language. Neither carries a boxed warning or requires a REMS program. Neither has an FDA safety communication specific to that individual drug beyond the class-wide complex sleep behavior warning. The two drugs differ in receptor binding profile and pharmacokinetics, and it is plausible that these differences could produce a different real-world safety balance between the two agents, but a rigorous head-to-head comparison of FAERS-reported event rates between suvorexant and lemborexant, adjusted for exposure, has not been demonstrated in the sources available for this review. Treat any specific numeric comparison between the two drugs' FAERS profiles as unverified until checked against a peer-reviewed source.

Decision framework: what a FAERS signal should and should not change

This framework is meant to help a reader translate "lemborexant has adverse event reports in FAERS" into an actual decision, since the raw fact that reports exist is not, by itself, actionable.

Step 1: Is the event already on the FDA label? Somnolence, sleep paralysis, complex sleep behaviors, and psychiatric symptom worsening are all already disclosed in the FDA-approved label. A FAERS report matching one of these is confirmation of a known risk, not a new discovery. It should prompt the same counseling and monitoring the label already recommends, not alarm.

Step 2: Does the patient carry a risk factor the pivotal trial did not test well? The SUNRISE trials excluded active major psychiatric illness and ran for about a month. A patient with a psychiatric history, a prior parasomnia, or a need for long-term nightly use sits outside what the pivotal data directly studied. For this patient, post-market reports carry more practical weight, and closer follow-up (for example, a check-in within two weeks of starting or changing dose) is a reasonable, low-cost step.

Step 3: Is the event reversible with dose reduction, or does it require discontinuation? Sleep paralysis is generally managed by dropping to 5 mg first. Complex sleep behavior of any kind (sleepwalking, sleep-driving, sleep-eating) is managed by stopping the drug, not by lowering the dose, per FDA guidance on the class.

Step 4: Does an interacting medication change the ceiling dose? Strong CYP3A inhibitors rule the drug out entirely; moderate CYP3A inhibitors cap the dose at 5 mg. This should be checked against the current label for the patient's specific concomitant medications rather than assumed from a general list.

Step 5: Can the patient guarantee the sleep window the drug requires? If a patient cannot reliably allow roughly 7 hours before needing to be alert (early shift work, on-call duties, caregiving), next-day impairment risk rises independent of any FAERS signal, and that alone may be reason to choose a different approach.

When FAERS data should prompt a conversation, not a decision on their own: any time a reader encounters a specific statistic (a rate, a reporting odds ratio, a percentage) attributed to lemborexant that is not accompanied by a citable, checkable source. Treat unsourced numbers as a prompt to ask a prescriber or pharmacist rather than as a basis for stopping or continuing a medication.

Evidence boundary: what is established, what is plausible, what is not established

Established: Lemborexant is FDA-approved for insomnia in adults; the label discloses somnolence, sleep paralysis, complex sleep behaviors, and psychiatric symptom warnings; the drug is contraindicated with strong CYP3A inhibitors and dose-limited with moderate ones; a single complex sleep behavior episode warrants discontinuation per FDA guidance for the sedative-hypnotic class.

Plausible but not established from the sources reviewed here: that lemborexant's higher orexin receptor binding potency produces a meaningfully different real-world safety profile than suvorexant; that DORAs as a class have an intrinsic pro-depressive effect beyond that expected from sedative-hypnotics generally; specific FAERS reporting-odds-ratio figures for sleep paralysis or complex sleep behaviors that have circulated in secondary summaries of this topic.

Not established: any precise incidence rate for these adverse events in real-world use, since FAERS cannot generate incidence rates by design.

Clinical takeaways

Starting at 5 mg, screening for psychiatric comorbidity and prior parasomnia before prescribing, giving written counseling on complex sleep behaviors, and arranging early follow-up are reasonable, label-consistent steps supported by the material reviewed here. Individual dosing decisions, and any decision to start, adjust, or stop lemborexant, should be made with a prescriber who can review the current FDA label and the patient's full medication list, since exposure-changing interactions and comorbidities materially affect the risk-benefit balance. Anyone experiencing a sleepwalking, sleep-driving, or sleep-eating episode should stop the medication and contact their prescriber promptly; this is not a symptom to manage by waiting it out.